vTv Therapeutics Inc. Capital Expenditures

Capital Expenditures of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital Expenditures for the quarter ending December 30, 2019 was $-68 Thousand (a -121.94% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures increased by 1260.0%
  • Annual Capital Expenditures for 2019 was $242 Thousand (a 3357.14% increase from previous year)
  • Annual Capital Expenditures for 2018 was $7 Thousand (a -128.0% decrease from previous year)
  • Annual Capital Expenditures for 2017 was $-25 Thousand (a -69.88% decrease from previous year)
  • Twelve month Capital Expenditures ending December 30, 2019 was $237 Thousand (a -22.3% decrease compared to previous quarter)
  • Twelve month trailing Capital Expenditures decreased by -2254.55% year-over-year
Trailing Capital Expenditures for the last four month:
30 Dec '19 29 Sep '19 30 Dec '18 29 Sep '18
$237 Thousand $305 Thousand $7 Thousand $-11 Thousand
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of vTv Therapeutics Inc.

Most recent Capital Expendituresof VTVT including historical data for past 10 years.

Interactive Chart of Capital Expenditures of vTv Therapeutics Inc.

vTv Therapeutics Inc. Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-0.07 $0.31 $0.24
2018 $0.0 $-0.01 $0.0 $0.01 $0.01
2017 $-0.02 $0.03 $0.0 $-0.04 $-0.03
2016 $0.0 $0.0 $-0.08 $-0.08
2015 $-0.04 $-0.01 $-0.03 $-0.0 $-0.08
2014 $0.34 $-0.01 $-0.03 $0.3
2013 $-0.15 $-0.16

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.